
TCR2 Therapeutics TCRR
Quartalsbericht 2023-Q1
hinzugefügt 11.05.2023
TCR2 Therapeutics Zahlungsmittel 2011-2026 | TCRR
Zahlungsmittel Jährlich TCR2 Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.7 M | 223 M | 94.2 M | 65.3 M | 48 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 223 M | 32.7 M | 92.5 M |
Zahlungsmittel Vierteljährlich TCR2 Therapeutics
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.4 M | 32.7 M | 54 M | 44.2 M | 74.1 M | 223 M | 262 M | 249 M | 218 M | 94.7 M | 94.2 M | 94.2 M | 94.2 M | 65.3 M | 65.3 M | 65.3 M | 65.3 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 20.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 262 M | 14.4 M | 91.9 M |
Zahlungsmittel anderer Aktien in der Pharmaeinzelhändler
| Name | Zahlungsmittel | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M | ||
|
BioNTech SE
BNTX
|
7.68 B | $ 91.21 | 0.03 % | $ 27.2 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
1.66 B | $ 330.79 | 3.74 % | $ 43.3 B | ||
|
BioLineRx Ltd.
BLRX
|
10.4 M | $ 2.34 | 5.72 % | $ 908 M | ||
|
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | ||
|
Cerus Corporation
CERS
|
20 M | $ 1.87 | 0.27 % | $ 356 M | ||
|
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
3.33 M | $ 0.46 | -13.08 % | $ 5.27 M | ||
|
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | ||
|
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | ||
|
CNS Pharmaceuticals
CNSP
|
7.2 M | $ 2.29 | 1.11 % | $ 1.02 M | ||
|
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
103 M | $ 2.97 | -0.67 % | $ 253 M | ||
|
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
709 M | $ 24.91 | 0.89 % | $ 3.05 B | ||
|
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
28.5 M | $ 10.08 | -0.88 % | $ 134 M | ||
|
Cardiff Oncology
CRDF
|
17.5 M | $ 1.59 | 0.32 % | $ 106 M | ||
|
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
3.22 M | - | 10.36 % | $ 9.8 M | ||
|
Curis
CRIS
|
5.06 M | $ 0.53 | -3.58 % | $ 6.98 M | ||
|
Aquestive Therapeutics
AQST
|
121 M | $ 4.1 | -0.85 % | $ 438 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
102 M | $ 37.76 | 1.42 % | $ 3.55 B | ||
|
CRISPR Therapeutics AG
CRSP
|
348 M | $ 49.35 | -0.32 % | $ 4.44 B | ||
|
CytomX Therapeutics
CTMX
|
12.7 M | $ 4.35 | -4.61 % | $ 600 M | ||
|
Citius Pharmaceuticals
CTXR
|
3.25 M | $ 0.88 | 2.44 % | $ 5.92 M | ||
|
Cue Biopharma
CUE
|
27.1 M | $ 0.17 | -6.06 % | $ 16.1 M | ||
|
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
231 M | $ 8.24 | 2.55 % | $ 226 M | ||
|
Cyclerion Therapeutics
CYCN
|
3.23 M | $ 4.13 | -32.85 % | $ 10.4 M | ||
|
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | ||
|
Daré Bioscience
DARE
|
24.7 M | $ 1.77 | 1.75 % | $ 19.8 M | ||
|
DBV Technologies S.A.
DBVT
|
194 M | $ 20.47 | -2.8 % | $ 2.86 B | ||
|
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B | ||
|
Celldex Therapeutics
CLDX
|
28.9 M | $ 31.46 | 1.29 % | $ 2.09 B | ||
|
Avenue Therapeutics
ATXI
|
2.86 M | - | -52.27 % | $ 4.45 M |